FOR RESEARCH USE ONLY
Early human researchSleep research

DSIP

Delta Sleep-Inducing Peptide researched for slow-wave sleep architecture and stress modulation.

01Slow-wave sleep02HPA axis03Circadian regulation
Molecular signature / dsip
Structural identity

Synthetic nonapeptide associated with delta-wave sleep research

Also known as

Delta Sleep-Inducing Peptide · Delta sleep nonapeptide

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. Across decades of research it has been studied for slow-wave sleep promotion, circadian regulation, stress-axis modulation and analgesic effects, with a notably benign tolerability profile.

The research question

DSIP research concerns sleep architecture rather than simple sedation. EEG measures, stress-axis activity and next-day function are more informative endpoints than sleep onset alone.

Section 02

Mechanism & research themes

Exact receptor target remains uncharacterised. Demonstrated effects include modulation of the HPA axis (reduced ACTH/cortisol output), normalisation of delta-wave EEG architecture, and interaction with opioidergic and GABAergic systems.

01

Increased slow-wave (delta) sleep duration in EEG studies

02

Reduced sleep latency and improved sleep continuity

03

Attenuation of stress-induced cortisol elevation

04

Reported analgesic activity in chronic-pain research

05

Possible normalisation of disrupted circadian rhythms

06

Favourable tolerability with minimal next-day sedation

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Small and often dated human studies sit alongside animal work. A defined receptor target and modern replicated dose–response evidence are still lacking.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 100–300mcg subcutaneously 30–60 minutes before bed, or intranasally. Cycles typically run 4–8 weeks with intermittent use rather than daily long-term administration.

Reported persistence

Plasma half-life is short (approximately 7–20 minutes), but downstream effects on sleep architecture persist well beyond clearance.

Calculator starting point

0.2 mg per reference dose

5 doses per week · 4-week cycle

2 mL default reconstitution volume

100–300 mcg SC pre-sleep, short cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate DSIP
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2–5mL bacteriostatic water for a 1–2.5mg/mL working concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months; -20°C for long-term storage. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Human RCT data is limited and dated; most evidence is mid-20th-century research.

L2

Receptor pharmacology remains poorly characterised — long-term safety profile is not well established.

L3

Mild dizziness or transient headache reported anecdotally at higher doses.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only